Stay current on the latest happenings in Wisconsin’s innovation community with these headlines:

Arrowhead Pharmaceuticals, which is based in Pasadena, CA, but houses its R&D operations in Madison, WI, provided updates on some of its drug candidates and development programs at two recent industry conferences.

At one of the meetings, Arrowhead (NASDAQ: ARWR) shared preclinical and phase 1 clinical data on ARC-AAT, the company’s drug candidate aimed at treating rare liver diseases associated with alpha-1 antitrypsin (AAT) deficiency. AAT deficiency is a genetic disorder that involves AAT molecules getting trapped inside the liver cells that produce them; liver disease can result from the buildup of AAT proteins in the organ. “Preclinical data suggest that treatment with ARC-AAT over time may improve liver health and prevent further damage,” Arrowhead said in a news release. Read the full story here.